Stratification	mace.Outcome	mace.HR (95% CI)	surv.Outcome	surv.HR (95% CI)
01.None:	! ! !		!!!!	
Q2 (12 – 14)	-	0.91 (0.89-0.93) ***	-	0.80 (0.78-0.83) ***
Q3 (15 – 16)	# 1 1 1 1	0.87 (0.84-0.89) ****	=	0.68 (0.65-0.70) ***
Q4 (> 16)	-	0.85 (0.83-0.88) ****	-	0.65 (0.63-0.68) ***
02.Age:65-69 years				
Q2 (12 – 14)	-	0.87 (0.83-0.91) **	-	0.71 (0.65–0.78) ***
Q3 (15 – 16)	-	0.79 (0.74-0.84) ****		0.59 (0.53-0.65) ***
Q4 (> 16)	-	0.81 (0.76–0.86) ****	-	0.57 (0.51–0.63) ***
02.Age:70-74 years		,		,
Q2 (12 – 14)	-	0.88 (0.85-0.92) **	-	0.85 (0.80–0.91) **
Q3 (15 – 16)	-	0.87 (0.83–0.92) ***	-	0.71 (0.66–0.76) ***
Q4 (> 16)	-	0.87 (0.83–0.91) ***	-=-	0.68 (0.63–0.73) ***
02.Age:75–79 years		0.07 (0.00 0.01)		0.00 (0.00 0.1 0)
Q2 (12 – 14)		0.94 (0.89–0.99)	- :	0.77 (0.72–0.82) ***
Q3 (15 – 16)		0.93 (0.88–1.00)		0.63 (0.58–0.68) ***
	-	0.86 (0.81–0.92) **	-	0.65 (0.60–0.70) ***
Q4 (> 16)		0.00 (0.01–0.92)		0.65 (0.60-0.70)
02.Age:80+ years	-	0.00 (0.02 4.04)		0.00 (0.70, 0.07) ***
Q2 (12 – 14)		0.99 (0.93–1.04)		0.82 (0.78–0.87) ***
Q3 (15 – 16)	-	0.90 (0.85–0.96) *	-	0.73 (0.68–0.77) ***
Q4 (> 16)	-	0.89 (0.83–0.95) *		0.68 (0.64–0.73) ***
03.Sex:Female			1 1 1	
Q2 (12 – 14)	-	0.89 (0.86–0.93) **	-	0.83 (0.78–0.87) ***
Q3 (15 – 16)	+	0.85 (0.82–0.89) ****	-	0.72 (0.68–0.77) ***
Q4 (> 16)	-	0.80 (0.77–0.84) ****	+	0.64 (0.60–0.68) ***
03.Sex:Male				
Q2 (12 – 14)	+ i i	0.92 (0.89-0.95) *	-	0.79 (0.76-0.83) ***
Q3 (15 – 16)	-	0.87 (0.84-0.91) ****	-	0.65 (0.62-0.68) ***
Q4 (> 16)	-	0.89 (0.85-0.92) ***	=	0.66 (0.63-0.69) ***
04.Race:Asian		,		,
Q2 (12 – 14)		→ 1.08 (0.73–1.59)		0.69 (0.42–1.15)
Q3 (15 – 16)		→ 1.21 (0.80–1.81)		0.42 (0.24–0.73) *
Q4 (> 16)		→ 1.18 (0.78–1.80)		0.36 (0.18–0.71) *
04.Race:Black		1.10 (0.70–1.00)		0.50 (0.10-0.71)
Q2 (12 – 14)		^{1→} 1.32 (1.13–1.55) *	- -	0.80 (0.67–0.97)
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		- 	
Q3 (15 – 16)		1.15 (0.97–1.36)	·	0.67 (0.55–0.82) **
Q4 (> 16)		0.84 (0.71–1.00)		0.63 (0.52–0.77) **
04.Race:Native American		(- 1) i		
Q2 (12 – 14)		0.30 (0.15–0.60) *	_	2.17 (0.78–6.02)
Q3 (15 – 16)		0.34 (0.18–0.67)		0.45 (0.17–1.21)
Q4 (> 16)		0.34 (0.18–0.64) *	1 1	→ 0.87 (0.32–2.39)
04.Race:Other				
Q2 (12 – 14)		→ 1.76 (1.06–2.91)		0.28 (0.12-0.63) *
Q3 (15 – 16)		→ 1.84 (1.08–3.14)	 = 	0.42 (0.20-0.88)
Q4 (> 16)		→ 1.24 (0.70–2.20)	-	0.59 (0.30-1.15)
04.Race:Unknown				
Q2 (12 – 14)		0.88 (0.77–1.01)		0.96 (0.81–1.14)
Q3 (15 – 16)	-	0.80 (0.69–0.93) *	-	0.89 (0.74–1.06)
Q4 (> 16)		0.83 (0.73–0.95)		0.86 (0.73–1.02)
04.Race:White		0.00 (0.10 0.00)		0.00 (0.70 1.02)
	= ! !	0.00 (0.88 0.02) ***	-	0.80 (0.77, 0.83) ***
Q2 (12 – 14)		0.90 (0.88–0.92) ***	·	0.80 (0.77–0.83) **
Q3 (15 – 16)		0.86 (0.83–0.88) ****		0.67 (0.65–0.70) **
Q4 (> 16)	_	0.86 (0.84–0.89) ****	_ _	0.65 (0.62–0.67) **
05.Low-income-subsidy/Dual Eligibility:No	_	0.01/0.01	i i i	
Q2 (12 – 14)	_	0.94 (0.91–0.96) *	_	0.82 (0.79–0.86) **
Q3 (15 – 16)	-	0.88 (0.85–0.91) ****	-	0.70 (0.67–0.74) **
Q4 (> 16)	•	0.87 (0.84–0.90) ****	- 1	0.66 (0.63–0.70) **
05.Low-income-subsidy/Dual Eligibility:Yes				
Q2 (12 – 14)	+	0.84 (0.80-0.88) ***	-	0.76 (0.72-0.81) **
Q3 (15 – 16)	-	0.83 (0.79–0.88) ****	i ! !	0.63 (0.59–0.68) **
Q4 (> 16)	-	0.80 (0.76–0.85) ****	-	0.63 (0.59–0.67) ***
-	24 25		0.4 0.7	
(0.1 0.5 1 1.2		0.1 0.5 1 1.	2
	HR		HR	